CoronaryAtlas logo
CoronaryAtlas
Triglycerides
Pathway / Lipid retention & oxidation

Triglycerides

lipid

Elevated triglycerides promote atherosclerotic lipid deposition and dysfunctional lipoprotein remodeling.

Pathway placement
Cascade stepLipid retention & oxidation
Confidencehigh
RationaleMI risk marker; atherogenic lipid burden; TGRL-driven atherosclerosis.
Druggability
Not assessed (no mapped human gene target).

Type I vs Type II discrimination

ScoresType-II-associated
R — rupture / Type-I
—
C — confounder / Type-II
50
A — assay feasibility
84
E — evidence strength
49
T1DI (composite)
13
Specificity differential (R−C)-35
Confounder panel (Type-II drivers)
1sepsis / systemic inflammationmag 2
2anemia / acute blood lossmag 1
3hypovolemia / dehydrationmag 2
4tachyarrhythmiamag 1
5hypoxemia / respiratory failuremag 2
6hypertensive emergencyn/a
7high-demand / peri-operative stressmag 1
Coverage: 6/7 confounders with evidence
Tier: deep-scored (abstract-extracted) · 9 supporting references. See the discrimination table for all markers.

Assay & specimen

Validated clinical assay
Specimen
Serum or plasma (fasting preferred)
Collection tube
Serum separator (gold/red-top, SST) · Lithium heparin (green-top)
Method / principle
Enzymatic (glycerol blanked)
Reagent / substrate
Lipase → glycerol; glycerol kinase + G3P oxidase + peroxidase Trinder
Platform
Automated analyzer
Turnaround · availability
Routine · Universal

Literature evidence(15)

Clinical trials(2)